prikaz prve stranice dokumenta Uloga androgenih receptora u karcinomu dojke
Access restricted to students and staff of home institution
master's thesis
Uloga androgenih receptora u karcinomu dojke
Rijeka: University of Rijeka, Faculty of Medicine, 2017. urn:nbn:hr:184:811639
Carović, Franjo
University of Rijeka
Faculty of Medicine
Department of General Pathology and Pathological Anatomy

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Carović, F. (2017). Uloga androgenih receptora u karcinomu dojke (Master's thesis). Rijeka: University of Rijeka, Faculty of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:184:811639

Carović, Franjo. "Uloga androgenih receptora u karcinomu dojke." Master's thesis, University of Rijeka, Faculty of Medicine, 2017. https://urn.nsk.hr/urn:nbn:hr:184:811639

Carović, Franjo. "Uloga androgenih receptora u karcinomu dojke." Master's thesis, University of Rijeka, Faculty of Medicine, 2017. https://urn.nsk.hr/urn:nbn:hr:184:811639

Carović, F. (2017). 'Uloga androgenih receptora u karcinomu dojke', Master's thesis, University of Rijeka, Faculty of Medicine, accessed 22 November 2024, https://urn.nsk.hr/urn:nbn:hr:184:811639

Carović F. Uloga androgenih receptora u karcinomu dojke [Master's thesis]. Rijeka: University of Rijeka, Faculty of Medicine; 2017 [cited 2024 November 22] Available at: https://urn.nsk.hr/urn:nbn:hr:184:811639

F. Carović, "Uloga androgenih receptora u karcinomu dojke", Master's thesis, University of Rijeka, Faculty of Medicine, Rijeka, 2017. Available at: https://urn.nsk.hr/urn:nbn:hr:184:811639

Metadata
TitleUloga androgenih receptora u karcinomu dojke
Title (english)The role of androgen receptors in breast carcinoma
AuthorFranjo Carović
MentorElvira Mustać (mentor)
Committee memberGordana Đorđević (predsjednik povjerenstva)
Committee memberNives Jonjić (član povjerenstva)
Committee memberInes Mrakovčić-Šutić (član povjerenstva)
GranterUniversity of Rijeka
Faculty of Medicine
(Department of General Pathology and Pathological Anatomy)
Rijeka
Defense date and country2017-07-14, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Oncology
Abstract
Karcinom dojke jedan je od najčešćih zloćudnih tumora u žena, kojem je incidencija u stalnom porastu. Kao i u većine tumora rana dijagnostika čini bitnu ulogu u uspješnom liječenju. Glavni problem u liječenju karcinoma dojke je predvidjeti, na osnovu kliničke manifestacije i morfoloških osobina tumora, njegovo daljnje ponašanje. U praksi je uvriježen naziv tzv. tradicionalnih prognostičkih čimbenika koji uključuju veličinu tumora, status limfnih čvorova te status hormonskih receptora. Takvi prognostički čimbenici i dalje predstavljaju nezaobilazan put u odluci o daljnjem liječenju. U zadnje vrijeme istraživanja karcinoma dojke su usmjerena prema mogućim terapijama kod dijagnoze trostruko negativnih karcinoma dojke. Takav trostruko negativan rezultat znači da rast karcinoma dojke nije potenciran hormonima estrogena i progesterona, niti prisutnošću HER-2 receptora. Oko 10-20 % karcinoma dojke klasificira se kao trostruko negativni, te ovakav podatak prisiljava liječnike na pronalazak novih lijekova koji bi potpomogli liječenje ovakve vrste karcinoma. U ovom dijelu nastupaju androgeni receptori. Ekspresija AR može biti korisna kao kriterij za subklasifikaciju trostruko negativnih karcinoma dojke na AR negativne i AR pozitivne karcinome koji mogu biti osjetljivi na antiandrogenu endokrinu terapiju. Ekspresija AR se pokazala kao važan prognostički čimbenik kod karcinoma dojke, a neovisan je prognostički čimbenik u odnosu na metastaze u limfnim čvorovima, veličinu tumora i status ER. Multivarijatne analize su pokazale da ekspresija AR korelira s općim preživljenjem bolesnika.
Abstract (english)
Breast cancer is the most common malignant tumor in women with increasing incidence. Early diagnosis plays an important role for successful treatment. The main problem in the treatment of breast cancer is to predict its further behavior based on clinical manifestations and morphological characteristics of the tumor. In practice we use so-called traditional prognostic factors that include tumor size, lymph node status, and hormone receptor status. Such prognostic factors continue to represent an unavoidable way in deciding on further treatment. Recently, breast cancer screening is focused on possible therapies in treating triple negative breast cancer. Such triple negative result means that breast cancer growth is not potentiated by hormones estrogen and progesterone, nor by the presence of HER-2 receptors. About 10-20% of breast cancers are classified as triple negative, and this information forces the doctors to find new drugs that could help treatment this type of cancer. Expression of AR may be useful as a criterion for the sub classification of triple negative breast cancer on AR negative and AR positive cancers that may be susceptible to anti-androgenic endocrine therapy. AR expression is provided to be an important prognostic factor in breast cancer and is an independent prognostic factor in relation to lymph node metastases, tumor size, and ER status. Multivariate analysis has shown that expression of AR correlates with the overall survival of the patient.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:184:811639
Study programmeTitle: Medicine
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsAccess restricted to students and staff of home institution
Terms of useLicence In copyright icon
Created on2017-11-21 12:00:17